Charlotte Fribert

Company: Toleranzia

Job title: CEO

Seminars:

Proteins as Tolerogens to Induce Antigen Specific Immune Tolerance 11:10 am

• Demonstrating TOL2’s potential as a disease-modifying treatment for myasthenia gravis, supported by preclinical efficacy, safety, and biomarker data NEW DATA • Discussing critical features of antigen-specific tolerogens to achieve clinical efficacy • Considerations for first in-human Phase I/IIa study of TOL2 in patients with generalized myasthenia gravisRead more

day: Conference Day One